nothing new except some colors on they might position the two RSV compounds in the future. Seems no partnership deal before the RSVHR data is out.
He clearly knows RSV would be extremely valuable if the data is solid. First (938) and best (323) in class.
Interesting how he redirected the immunology questions to Jennifer, maybe Jay will retire once they had a RSV deal and Jennifer will lead the company going forward on immun?
Market Data 
Markets 
AI
